Some time ago now I mentioned the work of Ass. Prof. Dr Daniel Thomas, in relation to upcoming Trials for patients w/ the CALR mutation.
Below, I have Posted (verbatim), the letter I have now received from Dr Daniel Thomas, for MATES Forum Patients to edify themselves...
Obviously, please also take his sound advice, and first discuss this Trial Option, with your own MPN Specialist before signing up. of course...
Best wishes
Steve
MPN-MATE RF
LETTER FROM ASS. PROF. DR Daniel Thomas
Associate Professor Daniel Thomas leads the Blood Cancer Program at the South Australian Health and Medical Research Institute, Adelaide. His team of scientists and clinicians recently developed a monoclonal antibody with specific activity for MPNs with CALR (calreticulin) mutations.
Dr Thomas says "There has never been a more exciting time in the history MPNs!
In the early 2000s imatinib from chronic myeloid leukaemia was a major breakthrough and then ruxolitinib/Jakafi for myelofibrosis in 2014 and then there was a lull. Now, we are realising there are new therapies for subtypes of MPN with CALR mutations, including essential thrombocythaemia and myelofibrosis.
Multiple groups around the world including our own in Australia, have developed new therapeutics for CALR mutant MPNs. These include antibody therapies and other forms of immunotherapy which have the potential to eradicate mutant CALR+ cells in blood and bone marrow.
Clinical trials will be opening very soon in Australia and I would strongly encourage patients to enrol after discussion with their haematologist. Available trials will be listed on the Australia-New Zealand Clinical Trials registry https://www.anzctr.org.au/TrialSearch.aspx, as well as regular updates through the Leukaemia Foundation and Australasian Leukaemia Lymphoma Group.
I am very thankful to all the patient supporters and advocacy groups that have helped me lobby for increased research into MPNs in Australia and in USA. Long term we are seeing many new ways to target JAK2 mutations based on the recent crystal structure which should have less side effects and more selectivity for mutant cells rather than healthy cells"
ANZCTR
The safety and scientific validity of each study registered on the ANZCTR is the responsibility of the study sponsor and investigators. Listing a study on the ANZCTR does not mean it has been endorsed by the ANZCTR.
www.anzctr.org.au
